The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma

The protein tyrosine phosphatase (PTP) family is involved in multiple cellular functions and plays an important role in various pathological and physiological processes. In many chronic diseases, for example cancer, PTP is a potential therapeutic target for cancer treatment. In the last two decades, dozens of PTP inhibitors which specifically target individual PTP molecules were developed as therapeutic agents. Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and is the second most lethal cancer worldwide due to a lack of effective therapies. Recent studies have unveiled both oncogenic and tumor suppressive functions of PTP in HCC. Here, we review the current knowledge on the involvement of PTP in HCC and further discuss the possibility of targeting PTP in HCC.

• Publication year

  2018

• Venue

  Cancers

• Publication date

  2018-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/cancers10030082PMID 29558404PMCID 5876657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis

  2017influential reference
• PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126

  2017cited by this paper
• Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients

  2017cited by this paper
• DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer

  2017cited by this paper
• Erratum to: Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma".

  2017cited by this paper
• Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma

  2017cited by this paper
• Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

  2017cited by this paper
• A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.

  2016cited by this paper
• SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma

  2016cited by this paper
• Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling.

  2016cited by this paper
• Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma

  2016cited by this paper
• Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression

  2016cited by this paper
• The Protein Tyrosine Phosphatase MEG2 Regulates the Transport and Signal Transduction of Tropomyosin Receptor Kinase A*

  2016cited by this paper
• Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3

  2016cited by this paper
• Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma

  2016cited by this paper
• Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance

  2016influential reference
• The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma

  2015cited by this paper
• SHP-1 is a negative regulator of epithelial–mesenchymal transition in hepatocellular carcinoma

  2015influential reference
• PTPRD is Homozygously Deleted and Epigenetically Downregulated in Human Hepatocellular Carcinomas

  2015cited by this paper
• Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development

  2015cited by this paper
• Protein tyrosine phosphatases in pathological process.

  2015cited by this paper
• Chemical composition of total flavonoids from Polygonum amplexicaule and their pro-apoptotic effect on hepatocellular carcinoma cells: Potential roles of suppressing STAT3 signaling.

  2015cited by this paper
• Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.

  2015cited by this paper
• Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor–induced epithelial‐mesenchymal transition

  2015cited by this paper
• PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.

  2015influential reference
• Development of Novel Triazolo-Thiadiazoles from Heterogeneous “Green” Catalysis as Protein Tyrosine Phosphatase 1B Inhibitors

  2015cited by this paper
• PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.

  2015cited by this paper
• Protein tyrosine phosphatase PTPN9 regulates erythroid cell development through STAT3 dephosphorylation in zebrafish

  2014cited by this paper
• SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma

  2014cited by this paper
• Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis.

  2014cited by this paper
• RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.

  2014cited by this paper
• Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer

  2014cited by this paper
• Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD–negative acute myeloid leukemia

  2014cited by this paper
• Leukocyte cell‐derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment

  2014cited by this paper
• Mutational and Functional Analysis of the Tumor‐Suppressor PTPRD in Human Melanoma

  2014cited by this paper
• Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.

  2014cited by this paper
• Hepatitis B virus X protein mutant HBxΔ127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT.

  2014influential reference
• Functional genomics identified a novel protein tyrosine phosphatase receptor type f‐mediated growth inhibition in hepatocarcinogenesis

  2014cited by this paper
• Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.

  2014cited by this paper
• Reduced Expression of PTPRD Correlates with Poor Prognosis in Gastric Adenocarcinoma

  2014cited by this paper
• Decreased Expression of PTPN12 Correlates with Tumor Recurrence and Poor Survival of Patients with Hepatocellular Carcinoma

  2014cited by this paper
• Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.

  2014cited by this paper
• STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma

  2014cited by this paper
• Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma

  2014cited by this paper
• Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma

  2014influential reference
• Discovery of novel src homology region 2 domain‐containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma

  2014cited by this paper
• A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.

  2014cited by this paper
• Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer.

  2013cited by this paper
• Bile acids activate YAP to promote liver carcinogenesis.

  2013cited by this paper
• Toll‐like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice

  2013cited by this paper
• SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model

  2013cited by this paper
• Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate

  2013cited by this paper
• Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.

  2013cited by this paper
• Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3

  2013cited by this paper
• Reciprocal Regulation of Protein Kinase and Pyruvate Kinase Activities of Pyruvate Kinase M2 by Growth Signals*

  2013cited by this paper
• Estrogen‐sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3

  2013influential reference
• Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells

  2013cited by this paper
• Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.

  2012cited by this paper
• The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma

  2012cited by this paper
• The Phosphatase PTP-PEST/PTPN12 Regulates Endothelial Cell Migration and Adhesion, but Not Permeability, and Controls Vascular Development and Embryonic Viability*

  2012influential reference
• Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma.

  2012cited by this paper
• Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.

  2012cited by this paper
• Radiotherapy and hepatocellular carcinoma: update and review of the literature.

  2012cited by this paper
• Upregulation of Protein Tyrosine Phosphatase Type IVA Member 3 (PTP4A3/PRL-3) is Associated with Tumor Differentiation and a Poor Prognosis in Human Hepatocellular Carcinoma

  2012cited by this paper
• Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer

  2012cited by this paper
• A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.

  2012cited by this paper
• Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox.

  2012cited by this paper
• Hepatocellular carcinoma

  2012cited by this paper
• Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma

  2012cited by this paper
• Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.

  2012cited by this paper
• Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3

  2011cited by this paper
• Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.

  2011cited by this paper
• Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.

  2011cited by this paper
• High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma

  2011cited by this paper
• γ‐Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro‐apoptotic and chemosensitizing agent

  2011cited by this paper
• SHP-1 in cell-cycle regulation.

  2011cited by this paper
• Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.

  2011cited by this paper
• SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer.

  2011cited by this paper
• Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.

  2011influential reference
• Epithelial Protein-Tyrosine Phosphatase 1B Contributes to the Induction of Mammary Tumors by HER2/Neu but Is Not Essential for Tumor Maintenance

  2011cited by this paper
• Tyrosine Phosphatases in the HER2-Directed Motility of Ovarian Cancer Cells: Involvement of PTPN12, ERK5 and FAK

  2011cited by this paper
• Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers

  2011cited by this paper
• A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene

  2010cited by this paper
• Protein-tyrosine Phosphatase PTPN9 Negatively Regulates ErbB2 and Epidermal Growth Factor Receptor Signaling in Breast Cancer Cells*

  2010influential reference
• The two faces of PTP1B in cancer.

  2010cited by this paper
• PTP-PEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells.

  2010cited by this paper
• Phosphatase of regenerating liver‐3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma

  2010cited by this paper
• Role of protein tyrosine phosphatase SHP2 in barrier function of pulmonary endothelium.

  2010cited by this paper
• Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

  2010cited by this paper
• Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas

  2010cited by this paper
• Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer

  2009cited by this paper
• Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

  2009cited by this paper
• Proinflammatory Mediators Upregulate Snail in Head and Neck Squamous Cell Carcinoma

  2009cited by this paper
• The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

  2009cited by this paper
• The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

  2009cited by this paper
• PTPσ Is a Receptor for Chondroitin Sulfate Proteoglycan, an Inhibitor of Neural Regeneration

  2009cited by this paper
• Protein tyrosine phosphatase SHP‐2: A proto‐oncogene product that promotes Ras activation

  2009cited by this paper
• Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.

  2009cited by this paper
• Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

  2008cited by this paper
• COOH-Terminal Truncated HBV X Protein Plays Key Role in Hepatocarcinogenesis

  2008cited by this paper

• Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update).

  2025cites this paper
• Metabolites involvement in the growth and spread of liver cancer

  2025cites this paper
• Unveiling racial disparities in prostate cancer using an integrative genomic and transcriptomic analysis

  2025cites this paper
• Downregulation of PTPRT elevates the expression of survivin and promotes the proliferation, migration, and invasion of lung adenocarcinoma

  2024cites this paper
• Microcystin-LR activates serine/threonine kinases and alters the phosphoproteome in human HepaRG cells.

  2024cites this paper
• Elucidation of escitalopram oxalate and related antidepressants as putative inhibitors of PTP4A3/PRL-3 protein in hepatocellular carcinoma: A multi-computational investigation

  2024cites this paper
• Non-Receptor Type PTPases and their Role in Controlling Pathways Related to Diabetes and Liver Cancer Signalling.

  2024cites this paper
• Impact of Protein Phosphatase Expressions on the Prognosis of Hepatocellular Carcinoma Patients

  2024cites this paper
• Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review)

  2023cites this paper
• Setting sail: Maneuvering SHP2 activity and its effects in cancer.

  2023cites this paper
• Identification of Novel Candidate Genes for Familial Thyroid Cancer by Whole Exome Sequencing

  2023cites this paper
• Oxidative Stress in Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Protein tyrosine phosphatase PTPL1 suppresses lung cancer through Src/ERK/YAP1 signaling

  2022cites this paper
• PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types

  2022cites this paper
• Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies

  2022cites this paper
• Characterization of somatic mutations and pathway alterations during hepatocellular carcinoma vascular invasion using next-generation sequencing

  2022cites this paper
• High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma

  2022cites this paper
• Association of PTPRT Mutations with Cancer Metastasis in Multiple Cancer Types

  2022cites this paper
• Uncovering Hidden Mechanisms of Different Prescriptions Treatment for Osteoporosis via Novel Bioinformatics Model and Experiment Validation

  2022cites this paper
• Tumor-Derived Exosomal Protein Tyrosine Phosphatase Receptor Type O Polarizes Macrophage to Suppress Breast Tumor Cell Invasion and Migration

  2021cites this paper
• Treatment of microglia with Anti-PrP monoclonal antibodies induces neuronal apoptosis in vitro

  2021cites this paper
• Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges

  2021cites this paper
• Protein Tyrosine Phosphatases: A new paradigm in an old signaling system?

  2021cites this paper
• Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model

  2021cites this paper
• The role of JAK/STAT signaling pathway and its inhibitors in diseases.

  2020cites this paper
• The upregulation of microRNA-223 promoted the apoptosis of liver cancer cells via TLR4

  2020cites this paper
• JAK/STAT pathway and molecular mechanism in bone remodeling

  2020cites this paper
• Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression

  2020cites this paper
• PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma

  2020cites this paper
• KIF15 Promotes Proliferation and Growth of Hepatocellular Carcinoma

  2020cites this paper
• The Long Noncoding RNA Ptprd-IR is a Novel Molecular Target for TGF-β1-Mediated Nephritis.

  2020cites this paper
• ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells

  2019cites this paper
• Protein Tyrosine Phosphatases in Tumor Progression and Metastasis: Promoter or Protection?

  2019influential citation
• Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma

  2019cites this paper
• An isoform-selective PTP1B inhibitor derived from nitrogen-atom augmentation of radicicol.

  2019cites this paper
• Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma

  2019cites this paper
• Targeting Tyrosine Kinases in Cancer: Lessons for an Effective Targeted Therapy in the Clinic

  2019cites this paper
• CXCL17 promotes cell metastasis and inhibits autophagy via the LKB1-AMPK pathway in hepatocellular carcinoma.

  2019cites this paper
• Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90

  2018cites this paper
• PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma

  2018cites this paper
• Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma

  2017cites this paper